A Phase 1, Double-blind, Placebo-controlled, Single-ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DCR-AUD in Healthy Volunteers
Latest Information Update: 03 May 2023
At a glance
- Drugs DCR-AUD (Primary)
- Indications Alcoholism
- Focus Adverse reactions
- Sponsors Dicerna Pharmaceuticals; Novo Nordisk
- 22 Mar 2023 Status changed from active, no longer recruiting to completed.
- 15 Sep 2022 Planned End Date changed from 1 Dec 2022 to 14 Dec 2022.
- 15 Sep 2022 Planned primary completion date changed from 1 Dec 2022 to 14 Dec 2022.